Monoamine Oxidase Inhibitors
暂无分享,去创建一个
[1] D. Luchins,et al. A review of combined tricyclic and MAOI therapy. , 1977, Comprehensive psychiatry.
[2] J. Sweeney,et al. A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl. A selective monoamine oxidase inhibitor. , 1989, Archives of general psychiatry.
[3] J. Stewart,et al. A possible L-deprenyl induced hypertensive reaction. , 1989, Journal of clinical psychopharmacology.
[4] A. J. Cooper. Tyramine and Irreversible Monoamine Oxidase Inhibitors in Clinical Practice , 1989, British Journal of Psychiatry.
[5] J. Ananth. Side effects in the neonate from psychotropic agents excreted through breast-feeding. , 1978, The American journal of psychiatry.
[6] G. Baumbacher,et al. Abuse of monoamine oxidase inhibitors. , 1992, The American journal of drug and alcohol abuse.
[7] D. Vartzopoulos,et al. Dependence on Monoamine Oxidase Inhibitors in High Dose , 1991, British Journal of Psychiatry.
[8] C. Pare,et al. The Present Status of Monoamine Oxidase Inhibitors , 1985, British Journal of Psychiatry.
[9] C. Noblet,et al. Life-threatening pseudophaeochromocytoma after toloxatone, terbutaline, and phenylephrine , 1993, The Lancet.
[10] M Wolfson,et al. Drug prescribing in renal failure: dosing guidelines for adults. , 1983, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[11] P. Tariot,et al. High-dose selegiline in treatment-resistant older depressive patients. , 1994, Archives of general psychiatry.
[12] J. P. Johnston. Some observations upon a new inhibitor of monoamine oxidase in brain tissue. , 1968, Biochemical pharmacology.
[13] O. Spigset,et al. Serotonin syndrome caused by a moclobemide-clomipramine interaction. , 1993, BMJ.
[14] G. Simpson,et al. Combined MAOI-tricyclic antidepressant treatment: a reevaluation. , 1981, Journal of clinical psychopharmacology.
[15] T. E. O'Brien,et al. Excretion of drugs in human milk. , 1974, American journal of hospital pharmacy.
[16] Tollefson Gd. Monoamine oxidase inhibitors: a review. , 1983, The Journal of clinical psychiatry.
[17] O. Suchowersky,et al. Interaction of Fluoxetine and Selegiline , 1990, Canadian journal of psychiatry. Revue canadienne de psychiatrie.
[18] W. Haefely,et al. On tyramine, food, beverages and the reversible MAO inhibitor moclobemide. , 1988, Journal of neural transmission. Supplementum.
[19] C. Funck-Brentano,et al. Pharmacokinetic and pharmacodynamic interaction between toloxatone, a new reversible monoamine oxidase‐A inhibitor, and oral tyramine in healthy subjects , 1992, Clinical pharmacology and therapeutics.
[20] P. Neuvonen,et al. Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses , 1993, The Lancet.
[21] D. Faulds,et al. Moclobemide : A Review of its Pharmacological Properties and Therapeutic Use in Depressive Illness. , 1992, Drugs.
[22] N. Moore,et al. Pseudo‐phaeochromocytoma after multiple drug interactions involving the selective monoamine oxidase inhibitor selegiline , 1995, Clinical endocrinology.
[23] R. Kerwin,et al. Rediscovering monoamine oxidase inhibitors. , 1989, BMJ.
[24] J. Knoll,et al. Deprenyl (selegiline): the history of its development and pharmacological action , 1983, Acta neurologica Scandinavica. Supplementum.
[25] J. Henry,et al. Fatal toxicity of antidepressant drugs in overdose. , 1987, British medical journal.
[26] M. Mayersohn,et al. Cimetidine alters the disposition kinetics of the monoamine oxidase‐A inhibitor moclobemide , 1991, Clinical pharmacology and therapeutics.
[27] Y. Lecrubier. Risk-Benefit Assessment of Newer Versus Older Monoamine Oxidase (MAO) Inhibitors , 1994, Drug safety.
[28] D. Spiker,et al. Combining tricyclic and monoamine oxidase inhibitor antidepressants. , 1976, Archives of general psychiatry.
[29] H. Sternbach. The serotonin syndrome. , 1991, The American journal of psychiatry.
[30] C. Waters. Fluoxetine and Selegiline – Lack of Significant Interaction , 1994, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[31] G. Zornberg,et al. Severe adverse interaction between pethidine and selegiline , 1991, The Lancet.
[32] P. Tyrer. Towards Rational Therapy with Monoamine Oxidase Inhibitors , 1976, British Journal of Psychiatry.
[33] O. Rascol,et al. Pseudophaeochromocytoma in parkinsonian patient treated with fluoxetine plus selegiline , 1993, The Lancet.